Plant-Based Biologics Market Expected to Reach $182.9 Million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Plant-Based Biologics Market," The plant-based biologics market size was valued at $116.10 million in 2021, and is estimated to reach $182.9 million by 2031, growing at a CAGR of 4.8% from 2022 to 2031.

Plant-based biologics industry have emerged as a possible alternative to traditional mammalian cell culture-based biologic production platforms, owing to their cost-effectiveness and scalability. The increase in demand for biologic medicines cannot be met solely by mammalian cell culture-based biologic manufacturing platforms, which prompts the investigation of alternate production platforms. Plant-based biologics have significant benefits over standard biologic production systems based on mammalian cell culture. Plants, for example, are capable of executing correct eukaryotic protein modification, which is crucial for the success of biologic medicines. Moreover, plants may produce biologic medicines at a lower cost and with greater scalability than mammalian cell culture-based biologic production systems, making them an appealing alternative. The advantages offered by plant-based biologics are not limited to cost-effectiveness and scalability. In addition, plant-based biologics can help in controlling potential pandemics with enhanced efficiency and care, making them an ideal platform for the production of biologic treatments. All these factors are anticipated to boost the plant-based biologics market share.

There is a growth in regulatory landscape for plant-based biologics, and navigating the complicated regulatory requirements for manufacturing and commercializing plant-based biologics can be difficult. Regulatory bodies may need additional testing and paperwork to assure the safety and efficacy of these items, which can raise the time and expense of development. These factors are anticipated to hinder the plant-based biologics market size.

Plant-based expression systems have emerged as a possible alternative to traditional mammalian and bacterial systems for the generation of commercially relevant proteins, including vaccines. The utilization of plants for protein manufacturing has various advantages, including cheaper production costs, scalability, and the ability to swiftly create vast amounts of proteins. Furthermore, plant-based expression systems are considered safe and environmentally friendly, and they can be used to produce proteins that are difficult or impossible to produce using other systems. Plant-based expression systems have the potential to revolutionize biologics manufacturing, providing a more sustainable and cost-effective alternative to traditional production methods with continuous research and development. These factors are anticipated to boost plant-based biologics market share in the upcoming years.

The global Plant-based biologics market analysis is segmented on the basis of product type, source, and region. On the basis of product type, it is classified into leaf-based, seed-based, fruit-based, and others. On the basis of source, it is classified into carrot, tobacco, rice, duckweed, and others. On the basis of target disease, it is classified into Gaucher disease, Fabry disease, and others. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in the Plant-based biologics market forecast report include Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., and Eleva GmbH.

The report offers a comprehensive analysis of the global plant-based biologics market trends by thoroughly studying various aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market. In addition, the report sheds light on the present scenario and upcoming trends & developments that contribute to the growth of the market. Moreover, restraints and challenges that hold power to obstruct the market growth are also profiled in the report along with Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and the emergence of substitutes in the market.

Impact of Covid-19 on the Global Plant-based biologics Industry

• Several clinical trials for plant-based biologics have been postponed or cancelled due to the pandemic. As a result, the rate of drug research and regulatory approvals has slowed down.
• The Covid-19 pandemic has raised the demand for vaccines, notably those made with plant-based biologics. However, the pandemic has highlighted the need for more agile and adaptive manufacturing systems that can quickly respond to emerging infectious diseases.
• The pandemic has resulted in greater investment in plant-based biologics research and development. Governments and commercial corporations invest in the development of new biologics and production methods that is anticipated to aid in the response to future pandemics and other global health issues.

Key Findings of the Study

• On the basis of product type, the leaf-based sub-segment emerged as the global leader in 2021, and seed-based is anticipated to be the fastest-growing sub-segment during the forecast period.
• On the basis of source, the tobacco sub-segment emerged as the global leader in 2021, and the duckweed sub-segment is predicted to show the fastest growth in the upcoming years.
• On the basis of target disease, the Fabry disease sub-segment emerged as the global leader in 2021, and the others sub-segment is predicted to show the fastest growth in the upcoming years.
• On the basis of region, the North America market registered the highest market share in 2021 and is projected to maintain the position during the forecast period.